Search
Crisaborole
go.drugbank.com/drugs/DB05219ApprovedInvestigationalCrisaborole is a novel oxaborole approved by FDA on December 14, 2016 as Eucrisa, a topical treatment of for mild to moderate atopic dermatitis. … It reduces the local inflammation in the skin and prevents further exacerbation of the disease with a good safety profile.
Betahistine
go.drugbank.com/drugs/DB06698ApprovedInvestigational[A220333,L16403] Betahistine was first approved by the FDA in the 1970s but withdrawn within approximately 5 years due to a lack of evidence supporting its efficacy. … It has a significant impact on both the physical and social functioning of affected individuals.
Products: BETAISTINA MYLAN GENERICS, BETAISTINA DOC GENERICIPeanut oil
go.drugbank.com/drugs/DB13964ApprovedWithdrawnThe kernels are consumed roasted but a large percentage is used for the production of vegetable oil. … [A33169] Under the FDA, peanut oil is categorized as an approved inactive ingredient for its use in drug products.
Lotilaner
go.drugbank.com/drugs/DB17992ApprovedInvestigationalVet approvedLotilaner is an ectoparasiticide that is a member of the isoxazoline family of compounds. … [A260741] On July 25, 2023, lotilaner was approved by the FDA for the treatment of Demodex blepharitis, making it the first and only approved therapeutic for this condition.[L47551]
AD 337
go.drugbank.com/drugs/DB05725InvestigationalAD 337 was under investigation in clinical trial NCT00377039 (A Multicentre Trial to Determine the Efficacy and Safety of AD-337 in the Treatment of Fibromyalgia).
Oregovomab
go.drugbank.com/drugs/DB04964InvestigationalOregovomab is a murine monoclonal antibody that attaches to the tumor-associated antigen CA125.
Categories: CA-125 AntigenTetrahydrocannabivarin
go.drugbank.com/drugs/DB11755InvestigationalCompared to THC which demonstrates its effects through weak partial agonist activity of both endocannabinoid receptors Cannabinoid-1 (CB1R) and Cannabinoid-2 (CB2R), THCV acts as a CB1 antagonist and a … Tetrahydrocannabivarin (THCV) is a propyl analogue of tetrahydrocannabinol (Δ9-THC), one of the primary pharmacological components of [Medical Cannabis].
Concizumab
go.drugbank.com/drugs/DB12820ApprovedInvestigational[L52043] Concizumab-mtci (Alhemo) was approved by the FDA in December 2024 for use in patients with hemophilia A or B with inhibitors. … Concizumab is a humanized IgG4 monoclonal antibody targeting the Kunitz-2 domain of tissue factor pathway inhibitor (TFPI), a key regulator of the coagulation cascade.
Tavokinogene telseplasmid
go.drugbank.com/drugs/DB17301InvestigationalTavokinogene telseplasmid consists of a DNA Plasmid Vector Encoding IL-12.
Synonyms: Dna plasmid encoding interleukin-12 ino-9012, DNA Plasmid Vector encoding IL-12 (pUMVC3-hIL-12-NGVL331)NNC-55-0396 free base
go.drugbank.com/drugs/DB17037ExperimentalNNC-55-0396 is a T-type Ca(2+) channel inhibitor.[A253047]